These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 31880125)

  • 1. [
    Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
    Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
    Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Coexistent BRAF
    Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
    Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer.
    Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
    Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations.
    Yu PC; Tan LC; Zhu XL; Shi X; Chernikov R; Semenov A; Zhang L; Ma B; Wang Y; Zhou XY; Ji QH; Wei WJ; Wang YL
    Endocr Pract; 2021 Jul; 27(7):698-705. PubMed ID: 33515759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
    Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
    Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
    Xing M; Liu R; Liu X; Murugan AK; Zhu G; Zeiger MA; Pai S; Bishop J
    J Clin Oncol; 2014 Sep; 32(25):2718-26. PubMed ID: 25024077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
    Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
    Sun J; Zhang J; Lu J; Gao J; Ren X; Teng L; Duan H; Lin Y; Li X; Zhang B; Liang Z
    PLoS One; 2016; 11(4):e0153319. PubMed ID: 27064992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of
    Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
    [No Abstract]   [Full Text] [Related]  

  • 15. Gene Expression Profiles of AHNAK2, DCSTAMP, FN1, and TERT Correlate With Mutational Status and Recurrence in Papillary Thyroid Carcinoma.
    Staubitz-Vernazza JI; Müller C; Heymans A; Nedwed AS; Schindeldecker M; Hartmann M; Kloth M; Schad A; Roth W; Musholt TJ; Hartmann N
    Genes Chromosomes Cancer; 2024 Aug; 63(8):e23256. PubMed ID: 39193983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.
    Na HY; Yu HW; Kim W; Moon JH; Ahn CH; Choi SI; Kim YK; Choi JY; Park SY
    Clin Endocrinol (Oxf); 2022 Jul; 97(1):106-115. PubMed ID: 35343605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent BRAF
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
    Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
    Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
    Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of the
    Liu R; Li Y; Chen W; Cong J; Zhang Z; Ma L; Chu L; Xiao H; Zhang Y; Liu Y; Xu Y; Yu Q; Yang X; Sun C
    Oncol Lett; 2020 Oct; 20(4):50. PubMed ID: 32802170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.